Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine

Clin Infect Dis. 2005 Sep 1;41(5):e45-7. doi: 10.1086/432581. Epub 2005 Jul 20.

Abstract

Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. Development of antibody to hepatitis e antigen did not prevent hepatic flare. One patient with marked bridging fibrosis required liver transplantation. Patients with advanced liver disease are at risk for hepatic flare with decompensation if active treatment is withdrawn (e.g., when highly active antiretroviral treatment is modified).

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Disease Progression
  • Drug Administration Schedule
  • Emtricitabine
  • Hepatitis B, Chronic / drug therapy*
  • Humans

Substances

  • Antiviral Agents
  • Deoxycytidine
  • Emtricitabine